Combination of cetuximab and PP242 synergistically suppress the progression of wild-type KRAS colorectal carcinoma

Mammalian target of rapamycin (mTOR) has been shown to be overactive in human colorectal cancer, but the first-generation mTOR inhibitor, rapamycin, has failed to show clinical efficacy against colorectal cancer. On the other hand, although the second-generation mTOR inhibitor, PP242, has exerted su...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Lei, Xia, Zuguang, Bian, Xinyu, Li, Guangchao, Hu, Jing, Cao, Ya, Wang, Qing, Qian, Xiaoping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4636092/
https://www.ncbi.nlm.nih.gov/pubmed/26586952
http://dx.doi.org/10.2147/OTT.S82453

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4636092/
https://www.ncbi.nlm.nih.gov/pubmed/26586952
http://dx.doi.org/10.2147/OTT.S82453

Ejemplares similares